ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Con
Date
2017-10-31
ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Confirmed in Both Signs and Symptoms
(if you want to view the body of article, click on the bottom link)
https://www.newswire.com/news/regentree-announces-the-results-of-the-arise-2-trial-with-rgn-259-for-20023743
(if you want to view the body of article, click on the bottom link)
https://www.newswire.com/news/regentree-announces-the-results-of-the-arise-2-trial-with-rgn-259-for-20023743